Nanoparticles exposing neurotensin tumor-specific drivers

Journal of Peptide Science

Volumn 19, Issue 4, 2013, Pages 198-204

  Falciani, Chiara ^a   Brunetti, Jlenia ^a   Lelli, Barbara ^a   Accardo, Antonella ^b   Tesauro, Diego ^b   Morelli, Giancarlo ^b   Bracci, Luisa ^a,c  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

Branched peptides; Doxorubicin; Liposome; Tumor targeting

Indexed keywords

ANTHRACYCLINE; LINEAR NEUROTENSIN PEPTIDE NT; LIPOSOME; NANOPARTICLE; NEUROTENSIN; TETRABRANCHED NEUROTENSIN PEPTIDE NT4; UNCLASSIFIED DRUG;

ARTICLE; CELL FUSION; CELL MEMBRANE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; INTERNALIZATION; PRIORITY JOURNAL; TARGET CELL; TUMOR CELL;

ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NANOPARTICLES; NEOPLASMS; NEUROTENSIN; PEPTIDES;

EID: 84875632201     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.2493     Document Type: Article

References (21)

1. Ohanian M, Cortes J, Kantarjian H, Jabbour E. Tyrosine kinase inhibitors in acute and chronic leukemias. Expert Opin. Pharmacother. 2012; 13(7): 927-38.
2. Markman B, Capdevila J, Elez E, Tabernero J. Immunotherapy New trends in epidermal growth factor receptor-directed monoclonal antibodies 2009; 1(6): 965-8.
3. Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. Clin. Cancer Res. 2011; 17(20): 6448-58.
4. Steiner M, Neri D. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin. Cancer Res. 2011; 17: 6406-16.
5. Ronca R, Sozzani S, Presta M, Alessi P. Delivering cytokines at tumor site: The immunocytokine-conjugated anti-EDB-fibronectin antibody case. Immunobiology 2009; 214(9-10): 800-10.
6. Gregoriadis G, Ryman BE. Lysosomal localization of β-fructofuranosidase-containing liposomes injected into rats. Some implications in the treatment of genetic disorders. Biochem. J. 1972; 129: 123-133.
7. Banciu M, Schiffelers RM, Storm G. Investigation into the role of tumor-associated macrophages in the antitumor activity of doxil. Pharm. Res. 2008; 25: 1948-1955.
8. Marcucci F, Lefoulon F. Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress. Drug Discov. Today 2004; 9: 219-228.
9. Torchilin VP. Antibody-modified liposomes for cancer chemotherapy. Expert Opin. Drug Delivery 2008; 5: 1003-1025.
10. Sofou S, Sgouros G. Antibody-targeted liposomes in cancer therapy and imaging. Expert Opin. Drug Delivery 2008; 5: 189-204.
11. Wu H-C, Chang D-K. Peptide-Mediated Liposomal Drug Delivery System Targeting Tumor Blood Vessels in Anticancer Therapy. J. Oncol. 2010; article ID: 723798; DOI:10.1155/2010/723798.
12. Falciani C, Accardo A, Brunetti J, Tesauro D, Lelli B, Pini A, Bracci L, Morelli G. Target-selective drug delivery through liposomes labeled with oligobranched neurotensin peptides. ChemMedChem 2011; 6(4): 678-85.
13. Bracci L, Falciani C, Lelli B, Lozzi L, Runci Y, Pini A, De Montis MG, Tagliamonte A, Neri P. Synthetic peptides in the form of dendrimers become resistant to protease activity. J. Biol. Chem. 2003; 278(47): 46590-5.
14. Falciani C, Lozzi L, Pini A, Corti F, Fabbrini M, Bernini A, Lelli B, Niccolai N, Bracci L. Molecular basis of branched peptides resistance to enzyme proteolysis. Chem. Biol. Drug Des. 2007; 69(3): 216-21.
15. Falciani C, Brunetti J, Pagliuca C, Menichetti S, Vitellozzi L, Lelli B, Pini A, Bracci L. Design and in vitro evaluation of branched peptide conjugates: turning nonspecific cytotoxic drugs into tumor-selective agents. ChemMedChem 2010; 5(4): 567-74.
16. Falciani C, Pini A, Bracci L. Oligo-branched peptides for tumor targeting: from magic bullets to magic forks. Expert Opin. Biol. Ther. 2009; 9(2): 171-8.
17. Falciani C, Fabbrini M, Pini A, Lozzi L, Lelli B, Pileri S, Brunetti J, Bindi S, Scali S, Bracci L. Synthesis and biological activity of stable branched neurotensin peptides for tumor targeting. Mol. Cancer Ther. 2007; 6(9): 2441-8
18. Falciani C, Lelli B, Brunetti J, Pileri S, Cappelli A, Pini A, Pagliuca C, Ravenni N, Bencini L, Menichetti S, Moretti R, De Prizio M, Scatizzi M, Bracci L. Modular branched neurotensin peptides for tumor target tracing and receptor-mediated therapy: a proof-of-concept, Curr. Cancer Drug Targets 2010; 10: 695-704.
19. Minervini A, Siena G, Falciani C, Carini M, Bracci L. Branched peptides as novel tumor-targeting agents for bladder cancer. Expert Rev. Anticancer Ther. 2012; 12(6): 699-701.
20. Chan WC, White PD. Fmoc Solid Phase Peptide Synthesis. Oxford University Press: New York, 2000.
21. Schmitt L, Dietrich C. Synthesis and characterization of chelator lipids for reversible immobilization of engineered proteins at self assembled lipid interfaces. J. Am. Chem. Soc. 1994; 116: 8485-8491.